![Pat Sacco](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Cobaugh Christian | M | - |
Vernal Biosciences, Inc.
![]() Vernal Biosciences, Inc. BiotechnologyHealth Technology Vernal Biosciences, Inc. is a fully integrated contract development and manufacturing organization (CDMO) that specializes in manufacturing and formulating mRNA and LNP-mRNA. Vernal's focus is on democratizing access to their expertise and unparalleled LNP-platform technologies to accelerate the potential of mRNA. The American company provides comprehensive high purity platform manufacturing solutions for mRNA-based medicines, from research to clinical development. Vernal Biosciences is pioneering the custom development and manufacturing process for a variety of applications including vaccine development, gene replacement, and more. The company was founded in 2021 and is headquartered just outside of an undisclosed location. The company was founded by Cobaugh Christian, who has been the CEO since incorporation. | - |
Joseph Higgins | M | - |
SalioGen Therapeutics, Inc.
![]() SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | 4 years |
Jason Cole | M | 51 |
SalioGen Therapeutics, Inc.
![]() SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | 1 years |
Gustavo Mahler | M | - |
Vernal Biosciences, Inc.
![]() Vernal Biosciences, Inc. BiotechnologyHealth Technology Vernal Biosciences, Inc. is a fully integrated contract development and manufacturing organization (CDMO) that specializes in manufacturing and formulating mRNA and LNP-mRNA. Vernal's focus is on democratizing access to their expertise and unparalleled LNP-platform technologies to accelerate the potential of mRNA. The American company provides comprehensive high purity platform manufacturing solutions for mRNA-based medicines, from research to clinical development. Vernal Biosciences is pioneering the custom development and manufacturing process for a variety of applications including vaccine development, gene replacement, and more. The company was founded in 2021 and is headquartered just outside of an undisclosed location. The company was founded by Cobaugh Christian, who has been the CEO since incorporation. | - |
Errik B. Anderson | M | - |
Vernal Biosciences, Inc.
![]() Vernal Biosciences, Inc. BiotechnologyHealth Technology Vernal Biosciences, Inc. is a fully integrated contract development and manufacturing organization (CDMO) that specializes in manufacturing and formulating mRNA and LNP-mRNA. Vernal's focus is on democratizing access to their expertise and unparalleled LNP-platform technologies to accelerate the potential of mRNA. The American company provides comprehensive high purity platform manufacturing solutions for mRNA-based medicines, from research to clinical development. Vernal Biosciences is pioneering the custom development and manufacturing process for a variety of applications including vaccine development, gene replacement, and more. The company was founded in 2021 and is headquartered just outside of an undisclosed location. The company was founded by Cobaugh Christian, who has been the CEO since incorporation. | - |
Sean Stalfort | M | 53 |
SalioGen Therapeutics, Inc.
![]() SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | - |
Sukumar Nagendran | M | 58 |
SalioGen Therapeutics, Inc.
![]() SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | - |
Daniella Kranjac | F | - |
Vernal Biosciences, Inc.
![]() Vernal Biosciences, Inc. BiotechnologyHealth Technology Vernal Biosciences, Inc. is a fully integrated contract development and manufacturing organization (CDMO) that specializes in manufacturing and formulating mRNA and LNP-mRNA. Vernal's focus is on democratizing access to their expertise and unparalleled LNP-platform technologies to accelerate the potential of mRNA. The American company provides comprehensive high purity platform manufacturing solutions for mRNA-based medicines, from research to clinical development. Vernal Biosciences is pioneering the custom development and manufacturing process for a variety of applications including vaccine development, gene replacement, and more. The company was founded in 2021 and is headquartered just outside of an undisclosed location. The company was founded by Cobaugh Christian, who has been the CEO since incorporation. | 1 years |
Craig Gordon | M | - |
SalioGen Therapeutics, Inc.
![]() SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Raymond Tabibiazar | M | 53 |
SalioGen Therapeutics, Inc.
![]() SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 10 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Pat Sacco
- Personal Network